Regenerative medicine startup Juventas completes phase 1 heart failure trial
Cleveland Clinic spinoff Juventas Therapeutics has successfully completed a phase 1 clinical trial of its regenerative medicine technology in heart failure patients. Cleveland-based Juventas’ technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels. In addition to heart failure patients, the company is investigating the treatment of patients suffering […]